Cysticercosis Unit, Instituto de Ciencias Neurologicas, Lima, Peru.
Trop Med Int Health. 2012 Aug;17(8):1014-8. doi: 10.1111/j.1365-3156.2012.03037.x. Epub 2012 Jul 19.
Neurocysticercosis (NCC) is endemic in most parts of the world and is now recognised as an important contributor to neurological disease. Serological diagnosis of NCC improved greatly in the past two decades and contributed to demonstrating previously unsuspected regions of endemicity. Claims for an accurate serological screening tool for human cysticercosis are frequently raised. However, after symptomatic therapeutics are applied, management of NCC is driven by the characteristics of the central nervous system infection in terms of viability, number, location size and evolutionary stage of parasites, as well as by the resulting inflammation. It is unclear whether, in the absence of neuroimaging, serological confirmation of aetiology of suspected cases (neurologically symptomatic) or detection of asymptomatic cases in population screening would affect their management or prognosis.
神经囊虫病（NCC）在世界上大多数地区流行，现已被认为是导致神经疾病的一个重要因素。过去二十年中，NCC 的血清学诊断有了很大的改善，并有助于发现以前未被怀疑的流行地区。人们经常声称有一种准确的血清学筛查工具可用于人类囊虫病。然而，在进行对症治疗后，NCC 的治疗取决于中枢神经系统感染的特征，包括寄生虫的活力、数量、位置、大小和进化阶段，以及由此产生的炎症。在没有神经影像学的情况下，血清学确认疑似病例（有神经系统症状）的病因，或在人群筛查中发现无症状病例，是否会影响其治疗或预后尚不清楚。
